Castuner

Écouter dans votre application

Épisodes

394 épisodes

  1. Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs 5:30
  2. Hyperkalemia as a Barrier to GDMT: Why “Stopping GDMT” Is Often the Wrong Reflex 8:45
  3. Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load 8:45
  4. The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion 5:45
  5. Potassium Binders to Optimize GDMT Therapy in HFrEF 6:45
  6. CKD, Diabetes, and Albuminuria: Keeping Kidney-Protective Therapy on Board Despite Hyperkalemia 9:00
  7. From Lab Alert to Action Plan: Monitoring Potassium Without Undermining Cardiorenal Protection 5:15
  8. The Binder Selection Playbook: Matching the Right Strategy to the Right Patient 17:15
  9. When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease 52:45
  10. Recurrence as the Rule: BD Symptoms Persist and Cycle 5:15
  11. Navigating the Limitations of Current BD Therapies 6:00
  12. Modulating the Bipolar Circuit: Striatal Dopamine and the Muscarinic Opportunity 5:00
  13. The Next Frontier: Addressing Persistent Cognitive Impairment in Bipolar Disorder 6:00
  14. Emerging Perspectives: The Potential Role of Xanomeline Trospium Across the Bipolar Spectrum 6:30
  15. The Hidden Danger of IgAN: Pathogenesis and Unmet Needs 6:00
  16. Unmasking IgAN: Achieving Earlier Diagnosis 6:45
  17. Proteinuria in IgAN: The Signal, The Target, and the Treatment Goal 6:30
  18. Navigating KDIGO Guidance in IgAN 4:15
  19. Mechanisms Matter! Optimizing Proteinuria Reduction In IgAN 4:30
  20. Translating Evidence into IgAN Care 8:45
  21. The Evolving Role of Biomarkers in IgAN 4:45
  22. The Future of IgAN Care 5:30
  23. Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders 5:15
  24. Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression 6:00
  25. The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape 7:30
  26. Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens 3:45
  27. Oral GLP-1 RA Therapy in Type 2 Diabetes and High Cardiovascular Risk 33:15
  28. Bridging the Bronchiectasis Gap: The Latest Emerging Multimodal Treatment Approaches 46:45
  29. Secondary Stroke Prevention: Antithrombotic Strategies for Neurologists, Hematologists, and Cardiologists 38:00
  30. Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy 9:00
  31. A New Lens on DKA: Leveraging the Latest Tech for Improved Patient Outcomes 16:45
  32. Patient Portal: Leveraging Technology to Improve Safety with Clinical Decision-Making for People with Diabetes 15:00
  33. CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs 36:45
  34. Treating Outside the Box: New Pathways to Retinal Vascular Stability 44:00
  35. Addressing the Burden of PH-ILD: Early Recognition, Evidence-Based Management, and Care Coordination 47:15
  36. Ready, Set, Act! Opportunities to Address Persistent Unmet Needs in Patients With HFrEF: A Case-Based Discussion 16:00
  37. Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma 5:30
  38. Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients 9:15
  39. Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma 5:15
  40. Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients 9:45
  41. Hypoparathyroidism – The Critical Role of Genetics in Your Differential Diagnosis 45:00
  42. Mineralocorticoid Receptor Antagonists in Heart Failure: The Evolving Treatment Landscape 55:00
  43. Overcoming Challenges in Transthyretin Cardiac Amyloidosis 58:45
  44. Frontline Champions: Nurses as Drivers of Symptom-Based CKD-aP Care 7:30
  45. CKD-aP Uncovered Prevalence & Pathophysiology 5:15
  46. When Itching Hurts: Quality of Life Disruption in CKD-aP 5:30
  47. Gabapentinoids: Safety Considerations and Downstream Outcomes 4:15
  48. From Scratch to Strategy: Talking About CKD-aP in Clinical Practice 5:00
  49. Spotlight on Assessment: Tools That Capture CKD-aP 7:30
  50. Reading Between the Lines: What PROMs Reveal About Itch 3:45